Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:

“ASCO25 Plenary: ATOMIC trial (A021502)

In stage III dMMR colon cancer, atezolizumab + FOLFOX cut recurrences by 50%
3-yr DFS: 86.4% vs 76.6%
HR: 0.50 | N=700+ | NCI-funded

Could this approach also benefit patients with high-risk stage II colon cancer?

Further studies are definitely needed, but this may open a promising door.”

Read OncoDaily’s Special Articles about ASCO 2025:

15 Posts Not to Miss from the 1st Day of ASCO 2025

15 Posts Not to Miss from the 2nd Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025

15 Posts Not to Miss from the 4thDay of ASCO 2025

Elvina Almuradova Shares ATOMIC Trial Results Showing Reduced Recurrence in dMMR Colon Cancer

“ASCO25 Plenary: ATOMIC trial (A021502)

In stage III dMMR colon cancer, atezolizumab + FOLFOX cut recurrences by 50%
3-yr DFS: 86.4% vs 76.6%
HR: 0.50 | N=700+ | NCI-funded

Further studies are definitely needed, but this may open a promising door.”

Elvina Almuradova Shares ATOMIC Trial Results Showing Reduced Recurrence in dMMR Colon Cancer

“ASCO25 Plenary: ATOMIC trial (A021502)

In stage III dMMR colon cancer, atezolizumab + FOLFOX cut recurrences by 50% 3-yr DFS: 86.4% vs 76.6% HR: 0.50 | N=700+ | NCI-funded

Further studies are definitely needed, but this may open a promising door.”

In stage III dMMR colon cancer, atezolizumab + FOLFOX cut recurrences by 50%
3-yr DFS: 86.4% vs 76.6%
HR: 0.50 | N=700+ | NCI-funded